MA43162A - Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton - Google Patents

Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton

Info

Publication number
MA43162A
MA43162A MA043162A MA43162A MA43162A MA 43162 A MA43162 A MA 43162A MA 043162 A MA043162 A MA 043162A MA 43162 A MA43162 A MA 43162A MA 43162 A MA43162 A MA 43162A
Authority
MA
Morocco
Prior art keywords
imidazopyrazine
inhibitors
tyrosine kinase
bruton tyrosine
bruton
Prior art date
Application number
MA043162A
Other languages
English (en)
French (fr)
Inventor
Tjeerd Barf
Zwart Edwin De
Dennis Demont
Niels Hoogenboom
Saskia Verkaik
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MA43162A publication Critical patent/MA43162A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA043162A 2015-11-06 2016-11-04 Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton MA43162A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252420P 2015-11-06 2015-11-06
US201562261228P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
MA43162A true MA43162A (fr) 2018-09-12

Family

ID=57286764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043162A MA43162A (fr) 2015-11-06 2016-11-04 Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton

Country Status (6)

Country Link
US (2) US10736893B2 (enExample)
EP (2) EP3371189A1 (enExample)
JP (1) JP6890602B2 (enExample)
CN (1) CN108602827B (enExample)
MA (1) MA43162A (enExample)
WO (1) WO2017077507A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
WO2018001331A1 (zh) 2016-06-30 2018-01-04 杭州华东医药集团新药研究院有限公司 一种咪唑吡啶胺苯基衍生物及其用途
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CA3055602A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
CA3058682A1 (en) * 2017-04-20 2018-10-25 Apotex Inc. Processes for the preparation of acalabrutinib and intermediates thereof
WO2019013562A1 (ko) * 2017-07-12 2019-01-17 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
KR102384924B1 (ko) 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
EP3706740A4 (en) * 2017-11-06 2021-07-28 Suzhou Pengxu Pharmatech Co., Ltd. METHOD FOR MANUFACTURING ACALABRUTINIB
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
CN108129483B (zh) * 2018-01-26 2019-06-04 成都施贝康生物医药科技有限公司 一种btk抑制剂及其应用
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
KR102106821B1 (ko) * 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN109053780B (zh) * 2018-07-05 2020-09-29 浙江合聚生物医药有限公司 一种抗肿瘤药物Acalabrutinib关键中间体的制备方法
MX2021002246A (es) 2018-08-29 2021-05-27 Acerta Pharma Bv Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida.
MY206135A (en) * 2018-09-14 2024-11-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Furo[3,4-b]pyrrole-containing btk inhibitor
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
CN113993871B (zh) * 2019-07-12 2023-08-01 正大天晴药业集团股份有限公司 含有5-氮杂螺庚烷的btk抑制剂
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230226049A1 (en) * 2020-06-19 2023-07-20 Acerta Pharma B.V. Acalabrutinib maleate dosage forms
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
MX2008015852A (es) 2006-06-14 2009-02-23 Imclone Systems Inc Formulaciones liofilizadas de anticuerpos anti-egfr.
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
KR101660050B1 (ko) 2008-01-04 2016-09-26 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
IN2014CN00408A (enExample) * 2011-07-19 2015-04-03 Merck Sharp & Dohme
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
US20180318297A1 (en) 2018-11-08
US11110088B2 (en) 2021-09-07
CN108602827B (zh) 2021-08-20
JP6890602B2 (ja) 2021-06-18
WO2017077507A1 (en) 2017-05-11
US20200330461A1 (en) 2020-10-22
EP3865485A1 (en) 2021-08-18
JP2018536705A (ja) 2018-12-13
US10736893B2 (en) 2020-08-11
CN108602827A (zh) 2018-09-28
EP3371189A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
IL279258B (en) tyrosine kinase inhibitors
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
MA42242A (fr) Inhibiteurs de la tyrosine kinase
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
LT3580220T (lt) Aminotriazolopiridinai, kaip kinazės inhibitoriai
DK3497086T3 (da) Aminopyrimidin-SSAO-inhibitorer
HUE050842T2 (hu) Janus-kináz inhibitor
CL2016002502A1 (es) Inhibidores de biaril cinasa
IL294381A (en) Pcna inhibitors
MA52814A (fr) Inhibiteurs de bromodomaine
BR112017002232A2 (pt) combinações de inibidor de tirosina quinase de bruton e usos das mesmas
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
EP3347008A4 (en) BETA-Lactamase INHIBITORS
EP3405192C0 (en) BRUTON'S TYROSINE KINASE INHIBITORS
DK3290418T3 (da) Janus Kinase (JAK)-hæmmere
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
BR112017022691A2 (pt) inibidor de bromodomínio.
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
ZA201808238B (en) Certain protein kinase inhibitors